Annexon, a Phase 1 biotech developing therapies for complement-mediated disorders, filed on Thursday with the SEC to raise up to $100 million in an initial public offering.
The company's first candidate, ANX005, is a full-length monoclonal antibody formulated for intravenous administration in autoimmune and neurodegenerative disorders. Its second candidate, ANX007, is an antigen-binding fragment formulated for intravitreal administration for the treatment of neurodegenerative ophthalmic disorders. The company has completed Phase 1b trials for ANX005 and ANX007 in patients with Guillain-Barré Syndrome (GBS) and glaucoma, respectively. It intends to advance ANX005 into a Phase 2/3 trial in GBS patients in developing countries in early 2021, and ANX007 into a Phase 2 trial in patients with geographic atrophy in 2021.
The South San Francisco, CA-based company was founded in 2011 and It plans to list on the Nasdaq under the symbol ANNX. Annexon filed confidentially on September 18, 2019. J.P. Morgan, BofA Securities, and Cowen are the joint bookrunners on the deal. No pricing terms were disclosed.
